Predicting response to therapy in chronic hepatitis C: An approach combining interleukin-28B gene polymorphisms and clinical data

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 279-285

  Ladero, José M ^a   Martin, Elena García ^b   Fernández, Cristina ^a   Carballo, Miguel ^c   Devesa, María J ^a   Martínez, Carmen ^b   Suárez, Avelina ^a   Díaz Rubio, Manuel ^a   Agúndez, José A ^b  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c HOSPITAL DE TERRASSA   (Spain)

Author keywords

Hepatitis C; Interferon 3; Interleukin 28B gene; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DNA; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84856140601     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06834.x     Document Type: Article

References (30)

1. European Association for the Study of the Liver Clinical Practice Guidelines. Management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-64.
2. Cuenca F, Fernández C, Devesa MJ etal. Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1. Rev. Esp. Enferm. Dig. 2010; 102: 234-8.
3. Mauss S, Hueppe D, John C etal. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J. Viral Hepat. 2011; 18: e81-90.
4. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Suppiah V, Moldovan M, Ahlenstein G etal. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 2009; 41: 1100-4.
6. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.
7. McCarthy JJ, Li JH, Thompson A etal. Replicated association between IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
8. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.
9. Stättermayer AF, Stauber R, Hofer H etal. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011; 9: 344-50.
10. Hayes CN, Kobayashi M, Akuta N etal. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 2011-7.
11. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
12. Honda M, Sakai A, Yamashita T etal. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
13. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol. 2011; 54: 439-48.
14. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1965-76.
15. Montes-Cano MA, García-Lozano JR, Abad-Molina C etal. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-7.
16. Rallón NI, Naggie S, Benito JM etal. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 15: F23-9.
17. Pineda JA, Caruz A, Rivero A etal. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C vírus. Clin. Infect. Dis. 2010; 51: 788-95.
18. The Spanish Association for the Study of the Liver. Consensus document of the Spanish Association for the Study of the Liver on then treatment of hepatitis B and C virus infection. Gastroenterol. Hepatol. 2006; 29 (Suppl. 2): 216-30.
19. Ladero JM, López-Alonso G, Devesa MJ etal. The "12 weeks stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label? Scand. J. Gastroenterol. 2008; 43: 979-83.
20. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996; 6: 989-94.
21. Witthöft TH, Möller B, Wiedmann KH etal. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German Open Safety Trial. J. Viral Hepat. 2007; 14: 788-96.
22. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
23. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 2003; 73: 1162-9.
24. Agúndez JA, Golka K, Martínez C, Selinski S, Blaszkewicz M, García-Martín E. Inravelin ambiguous NAT2 genotyping data. Clin. Chem. 2008; 54: 1390-4.
25. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J. Gastroenterol. 2010; 45: 903-10.
26. Dill MT, Duong FH, Vogt JE etal. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-31.
27. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 2011; 54: 408-14.
28. Sarrazin C, Susser S, Doehring A etal. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011; 54: 415-21.
29. Scherzer T-M, Hofer H, Staettermayer AF etal. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with interferon alfa-2a and ribavirin. J. Hepatol. 2011; 54: 866-71.
30. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.